Navigation Links
Atherotech to Exhibit The VAP Test at ADA 2008 Meeting in San Francisco
Date:5/28/2008

VAP expanded cholesterol test can help clinicians identify best treatment

options for patients at risk of heart disease

BIRMINGHAM, Ala., May 28 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP Cholesterol Test in booth No. 4202 at the American Diabetes Association 68th Annual Scientific Sessions. The annual meeting takes place June 6 - 10, 2008, at the Moscone Convention Center in San Francisco.

The VAP(R) Cholesterol Test (Atherotech, Inc.) is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the recent expert consensus guidelines from the American Diabetes Association and American College of Cardiology. The VAP Test can identify more than twice the number of lipid abnormalities (the No. 1 risk factor of heart disease) than the standard cholesterol test, and is the only cholesterol test to identify markers for Metabolic Syndrome, a precursor for diabetes.

"We're pleased to be presenting our advanced lipid profile to health care professionals at the premier conference for diabetes research and information," said Atherotech Chief Medical Officer James Ehrlich, M.D. "The conference enables us to explain one-on-one how detailed risk profiling is changing the way we evaluate and manage dyslipidemias in at-risk patients."

People with a family history or an existing condition of diabetes, high blood pressure or heart disease -- or who are already taking cholesterol lowering medication -- are candidates for the comprehensive VAP Test. In addition, those who didn't score within the desirable ranges of the standard cholesterol test (i.e. those with Triglycerides > 150, HDL < 40, LDL >130, Total Cholesterol > 200) should also opt for the more detailed VAP Test.

Atherotech representatives will be available to discuss the VAP expanded cholesterol test in booth 4202, and blood draws will be provided to qualified attendees. Test results will be returned via mail after the conference.

The VAP Test is available nationwide. For more information call 877.901.8510 or visit http://www.thevaptest.com.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP technology, which directly measures the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for LDL measurement and the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Cholesterol Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit http://www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific to Exhibit at the DPRWorld(TM) 08 in Las Vegas, Nevada
2. Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
3. Tomorrows Top Designers Advance DVT Awareness at Parsons AAS Line Debut Exhibition
4. Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting
5. Photo: Bryan Adams Unveils Hear the World Ambassadors Photo Exhibit
6. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
7. Milestone Scientific to Exhibit at the California Dental Association (CDA) Spring Scientific Session
8. Global Sound Conference Invites Los Angeles Residents to Experience the Latest in Stress Relief with Free Exhibits, Live Music, Movie Screenings and More
9. China Sky One Medical, Inc. Announces Its Successful Participation in the 20th International Medical Instruments and Equipment Exhibition
10. Mindray to Exhibit at 2008 China International Medical Equipment Fair
11. Natural Harmony Foods to Exhibit in Multiple Venues in 08
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... More than a third of American adults are considered obese, says the ... increased attention in recent years, as an article published May 18th on ... people are familiar with the basic requirements of maintaining a healthy diet and exercise ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... care world, this installment is bolstered by inspiring human interest stories, courtesy of ... the developing trends and tech within the industry, from leading advocates and associations—namely ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research ... their dogs straight off the grill. Of the 90 percent of Americans who say ... a hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its Connor Cares ... the Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s ... surfaces in all forms and levels of the game, Connor Sports has committed to ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... study highlights the necessity of health literacy within the technology advancement of diagnostic imaging. According ... , a majority of oncology patients undergo imaging screenings without understanding the nuanced risks ... ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... , May 27, 2016 ... biopharmaceutical company focused on late-stage drug development, today ... Pharma of pivotal batches required for registration ... Administration (FDA). This follows Kitov,s announcement ... trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
Breaking Medicine Technology: